X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

AFMD

Closed

Affimed Nv

0.0761
-0.1054 (-58.07%)
Last Update: 18 Jun 2025 16:30:00
Yesterday: 0.1815
Day's Range: 0.0725 - 0.098
Send
When Written:
 
0.7412
Affimed NV is a clinical-stage biopharmaceutical company that specializes in the development of targeted immunotherapies for cancer treatment. The company's proprietary platform, called ROCK (Redirected Optimized Cell Killing), is designed to harness the power of the immune system to selectively target cancer cells while sparing healthy cells.

Affimed's lead product candidate is AFM13, a bispecific antibody that targets CD30-positive lymphomas. The company also has a pipeline of other product candidates in various stages of development, including AFM24 for the treatment of solid tumors and AFM13 for the treatment of other CD30-positive cancers.

Affimed was founded in 2000 and is headquartered in Heidelberg, Germany, with a subsidiary in Rockville, Maryland, USA. The company is publicly traded on the NASDAQ under the ticker symbol AFMD.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X